| Literature DB >> 32627973 |
Zhuo Liu1, Li Zhang2, Peng Hong1, Liwei Li2, Shiying Tang1, Xun Zhao1, Qiming Zhang1, Guodong Zhu1, Ran Peng3, Binshuai Wang1, Zhigang Chen1, Zhenghui Sun1, Feilong Yang1, Guoliang Wang1, Xiaojun Tian1, Shudong Zhang1, Yi Huang1, Hongxian Zhang1, Cheng Liu1, Shumin Wang2, Lulin Ma1.
Abstract
OBJECTIVE: To describe the clinical characteristics of renal cell carcinoma (RCC) with venous tumor thrombus (VTT) and bland thrombus (BT), and to evaluate the influence of BT on surgical treatment and cancer-specific survival (CSS) of RCC with VTT.Entities:
Keywords: bland thrombus; prognosis; renal cell carcinoma; surgical treatment
Mesh:
Year: 2020 PMID: 32627973 PMCID: PMC7433832 DOI: 10.1002/cam4.3264
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
The imaging diagnostic criteria of venous tumor thrombus combined with bland thrombus
| Item | Content | TT | BT |
|---|---|---|---|
| Enhanced CT | Width of the involved vein | Widened | Widened or normal |
| Shape of thrombus | Irregular | Regular | |
| The edge of thrombus | Rough | Smooth | |
| Enhanced scanning | Enhanced | Not enhanced; relatively low density | |
| Enhanced MRI | T1WI sequence | Low signal | High signal |
| T2WI sequence | Uneven signal | Uniform signal | |
| DWI sequence | Local or total high signal | Low signal | |
| Contrast‐enhanced imaging | Uneven enhancement; enhanced degree similar to tumor; neovascularization | No enhancement; low signal |
Abbreviations: BT, bland thrombus; CT, computed tomography; MRI, magnetic resonance imaging; TT, tumor thrombus.
Bland thrombus classification according to the relative position of bland thrombus
| BT classification | Definition | Number, n (%) | Preoperative diagram | Postoperative diagram |
|---|---|---|---|---|
| Group A | Proximal end BT | 1 (4.8%) |
|
|
| Group B | BT in the contralateral renal vein | 2 (9.5%) |
|
|
| Group C | Distal end BT | 12 (57.1%) |
|
|
| Group D | Multiple BT | 6 (28.6%) |
|
|
Abbreviation: BT, bland thrombus.
FIGURE 1A 58‐year‐old man with right renal cell carcinoma (RCC) with inferior vena cava (IVC) tumor thrombus (TT). (A) Abdominal enhanced magnetic resonance imaging (coronal position) showed the widening of the IVC and TT in the lumen (red arrow). The extent of IVC involvement was about 11.6 cm. Filling defect was seen at the entrance of renal vein into IVC and distal end of the IVC, suggesting the presence of bland thrombosis (BT) (black arrow). (B) Exposure of IVC and related vessels: distal end of IVC, contralateral renal artery or vein, proximal end of IVC. BT in the right renal vein and IVC. The distal end of the IVC and bilateral common iliac and external iliac veins had BTs. (C) We exposed the IVC by dissociating the duodenum to the inside of the abdomen. We transected the distal end of the IVC, contralateral renal vein, and proximal end of the IVC. The right kidney and the TT were removed completely. (D) Postoperative gross specimen showed right renal tumor and IVC TT combined with distal BT
Comparison of clinical and pathologic characters between bland thrombus (BT) patients and non‐BT patients
| Non‐BT (n = 102) | BT patients (n = 21) |
| |
|---|---|---|---|
| Gender, n (%) | 1.000 | ||
| Male | 76 (74.5%) | 16 (76.2%) | |
| Female | 26 (25.5%) | 5 (23.8%) | |
| Age, y, mean ± SD | 58.56 ± 10.56 | 59.00 ± 13.89 | .870 |
| BMI, kg/m2, mean ± SD | 23.56 ± 4.00 | 23.93 ± 3.68 | .696 |
| Side, n (%) | .340 | ||
| Left | 41 (40.2%) | 8 (38.1%) | |
| Right | 61 (59.8%) | 13 (61.9%) | |
| ASA grade, n (%) | .335 | ||
| 1 | 8 (7.8%) | 0 (0%) | |
| 2 | 81 (79.4%) | 12 (57.1%) | |
| 3 | 13 (12.7%) | 9 (42.9%) | |
| Clinical symptoms, n (%) | .126 | ||
| No clinical symptoms | 29 (28.4%) | 3 (14.3%) | |
| Local symptoms | 42 (41.2%) | 10 (47.7%) | |
| Systemic symptoms | 15 (14.7%) | 2 (9.5%) | |
| Both | 16 (15.7%) | 6 (28.5%) | |
| Clinical N stage, n (%) | .336 | ||
| cN0 | 48 (47.1%) | 7 (33.3%) | |
| cN1 | 54 (52.9%) | 14 (66.7%) | |
| Clinical M stage, n (%) | |||
| cM0 | 70 (68.6%) | 14 (66.7%) | .304 |
| cM1 | 32 (31.4%) | 7 (33.3%) | |
| Mayo classification, n (%) | <.001 | ||
| 0 | 28 (27.5%) | 0 (0%) | |
| I | 34 (33.3%) | 1 (4.8%) | |
| II | 24 (23.5%) | 10 (47.6%) | |
| III | 9 (8.8%) | 5 (23.8%) | |
| IV | 7 (6.9%) | 5 (23.8%) | |
| Hemoglobin, g/L, mean ± SD | 122.89 ± 23.76 | 112.38 ± 19.44 | .060 |
| Platelet count, ×109/L, mean ± SD | 245.34 ± 100.82 | 230.00 ± 73.81 | .510 |
| Serum calcium, mg/dL, mean ± SD | 8.71 ± 0.81 | 8.55 ± 0.47 | .405 |
| Albumin, g/L, mean ± SD | 38.29 ± 5.88 | 38.32 ± 5.67 | .982 |
| Alkaline phosphatase, U/L, mean ± SD | 93.46 ± 47.35 | 103.43 ± 60.28 | .404 |
| Preoperative serum creatinine, µmol/L, mean ± SD | 97.88 ± 56.98 | 103.71 ± 27.14 | .648 |
| Tumor diameter, cm, mean ± SD | 8.94 ± 3.50 | 7.64 ± 2.84 | .113 |
| Maximum width of VTT, mm, mean ± SD | 20.28 ± 8.94 | 32.29 ± 7.01 | <.001 |
| The width of VTT at the entrance of the renal vein, mm, mean ± SD | 17.86 ± 6.74 | 26.99 ± 4.47 | <.001 |
| Surgical approach, n (%) | .006 | ||
| Laparoscope | 54 (52.9%) | 4 (19.0%) | |
| Open | 48 (47.1%) | 17 (81.0%) | |
| IVC transverse resection, n (%) | .001 | ||
| No | 92 (90.2%) | 9 (42.9%) | |
| Yes | 10 (9.8%) | 12 (57.1%) | |
| Operative time, min, mean ± SD | 314.86 ± 123.00 | 416.76 ± 103.61 | .001 |
| Surgical blood loss, mL, mean ± SD | 1090.98 ± 1395.21 | 2738.10 ± 2238.41 | .004 |
| Red blood cell transfusion, mL, mean ± SD | 624.51 ± 926.87 | 1933.33 ± 2036.99 | .009 |
| Plasma transfusion, mL, mean ± SD | 171.57 ± 390.07 | 619.05 ± 831.64 | .025 |
| Pathology type, n (%) | .747 | ||
| Clear cell RCC | 86 (84.3%) | 17 (81.0%) | |
| Non‐clear cell RCC | 16 (15.7%) | 4 (19.0%) | |
| Sarcomatoid differentiation, n (%) | 18 (17.6%) | 4 (19.0%) | 1.000 |
| Serum creatinine one week after operation, µmol/L, mean ± SD | 113.13 ± 102.98 | 167.62 ± 203.73 | .245 |
| Postoperative complication, n (%) | 28 (27.5%) | 15 (71.4%) | .011 |
| Postoperative adjuvant targeted therapy, n (%) | 60 (58.8%) | 11 (52.4%) | .814 |
Prognosis factors for renal cell carcinoma patients with venous tumor thrombus
| Items | Univariable analysis | Multivariable analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI |
| HR | 95% CI |
| |
| M1 stage | 3.499 | 1.726‐7.091 | <.001 | 3.356 | 1.488‐7.568 | .004 |
| Mayo classification | 2.207 | 1.439‐3.385 | <.001 | — | — | .830 |
| Maximum width of tumor thrombus | 1.158 | 1.085‐1.236 | <.001 | — | — | .986 |
| Operative approach | 2.157 | 1.023‐4.547 | .043 | — | — | .884 |
| IVC resection | 6.900 | 2.336‐20.379 | <.001 | — | — | .361 |
| Operative time | 1.007 | 1.003‐1.011 | .001 | — | — | .761 |
| Surgical bleeding volume | 1.000 | 1.000‐1.001 | .001 | 1.000 | 1.000‐1.001 | .043 |
| Surgical blood transfusion volume | 1.001 | 1.000‐1.001 | .001 | — | — | .654 |
| Plasma transfusion volume | 1.001 | 1.000‐1.002 | .002 | — | — | .915 |
| The width of tumor thrombus at the entrance of the renal vein | 1.236 | 1.109‐1.379 | <.001 | 1.220 | 1.089‐1.366 | .001 |
| Sarcomatoid differentiation | 4.039 | 1.962‐8.314 | <.001 | 6.875 | 2.907‐16.260 | <.001 |
| Clear cell RCC | 2.850 | 1.337‐6.075 | .007 | 3.171 | 1.257‐7.999 | .015 |
| Elevated alkaline phosphatase | 3.120 | 1.474‐6.604 | .003 | 2.543 | 1.102‐5.869 | .029 |
| BT | 2.271 | 1.008‐5.121 | .048 | 3.323 | 1.378‐8.012 | .007 |
Abbreviations: BT, bland thrombus; CI, confidence interval; HR, hazard ratio; RC, renal cell carcinoma.
FIGURE 2Cancer‐specific survival of bland thrombus (BT) and non‐BT patients